Phio Pharmaceuticals Sees Promising Tumor Response in Clinical Trial
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced positive results from its ongoing Phase 1b clinical study for treating cutaneous Squamous Cell Carcinoma, melanoma, and Merkel cell carcinoma. The company’s INTASYL siRNA gene silencing technology aims to enhance the ability of immune cells to kill cancer cells. In the trial, six patients with cutaneous Squamous Cell Carcinoma … Read more